Article
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
PloS one - 1 Jan 2022
Koyama Kumiko, Ishikawa Hirokazu, Abe Manabu, Shiose Yoshinobu, Ueno Suguru, Qiu Yang, Nakamaru Kenji, Murakami Masato
Abstract excerpt
ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them potential therapeutic targets. In the current study, antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3 directed antibody drug conjugate, was evaluated in tumor models with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.